Executive leadership at Pasithea Therapeutics.
Board of directors at Pasithea Therapeutics.
Research analysts covering Pasithea Therapeutics.
Recent press releases and 8-K filings for KTTA.
Pasithea Therapeutics Corp. Stockholders Approve Increase in Authorized Shares and Stock Incentive Plan Shares
KTTA
Proxy Vote Outcomes
Executive Compensation
- On January 28, 2026, Pasithea Therapeutics Corp. held a Special Meeting of Stockholders where key proposals were approved.
- Stockholders approved an amendment to the company's Certificate of Incorporation, increasing the authorized common stock from 100,000,000 shares to 500,000,000 shares. This amendment became effective upon filing on January 28, 2026.
- Stockholders also approved an amendment to the 2023 Stock Incentive Plan, increasing the maximum aggregate number of shares authorized for issuance by 11,985,779 shares, bringing the total to 14,000,000 shares. This amendment became effective following its approval.
Jan 28, 2026, 9:15 PM
Pasithea Therapeutics Updates PAS-004 Clinical Trial Timelines and Recent Financing
KTTA
New Projects/Investments
Guidance Update
- Pasithea Therapeutics provided updated timelines for its PAS-004 clinical programs, a next-generation oral macrocyclic MEK inhibitor.
- For the Phase 1/1b clinical trial in adult NF1-PN patients, the company plans to present data, including efficacy, safety, tolerability, and pharmacokinetic (PK) data, in the second half of 2026.
- In the Phase 1 clinical trial in advanced cancer patients, Pasithea expects to present longer-term follow-up data from Cohort 4 through Cohort 8 in the second quarter of 2026.
- The company successfully raised $60 million in gross proceeds through a public offering in December 2025, which is expected to support operations through at least the first half of 2028.
Jan 13, 2026, 12:01 PM
Pasithea Therapeutics Announces Positive Interim Phase 1 Data for PAS-004 in Advanced Cancer Study
KTTA
New Projects/Investments
- Pasithea Therapeutics Corp. reported positive interim Phase 1 data for its drug candidate PAS-004 in patients with advanced solid tumors.
- A BRAF V600E melanoma patient in Cohort 4A (15mg capsule) achieved an unconfirmed partial response with a -31.9% tumor reduction and remained on trial for over 11 months.
- The study demonstrated a Disease Control Rate (DCR) of 71.4% (5 of 7) for patients with BRAF-mutated tumors and 42.8% (9 of 21) for all efficacy evaluable patients.
- PAS-004 was well-tolerated across all dose levels through Cohort 6, with no dose-limiting toxicities (DLTs) and no discontinuations reported among 27 dosed patients.
Nov 25, 2025, 9:15 PM
Pasithea Therapeutics Announces Clinical Trial Site Activation
KTTA
New Projects/Investments
- Pasithea Therapeutics Corp. announced on November 4, 2025, the activation of a new U.S. clinical trial site at the University of Alabama at Birmingham (UAB) for its ongoing Phase 1/1b open-label study of PAS-004.
- The study evaluates PAS-004, a next-generation macrocyclic oral MEK inhibitor, in adult patients with neurofibromatosis type 1 (NF1) with symptomatic and inoperable, incompletely resected, or recurrent plexiform neurofibromas.
- Enrollment at the UAB site is expected to begin immediately.
- Pasithea will also serve as Platinum Sponsor of the 2025 NF Caregivers Symposium hosted at UAB on November 8, 2025.
Nov 4, 2025, 12:04 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more